Vaccine News – Study – Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12

Study – Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants.

US National Library of Medicine
National Institutes of Health – Oct 2013

Colafrancesco S – 1, Perricone C, Tomljenovic L, Shoenfeld Y.
Author information
1 Zabludowicz Center for Autoimmune Diseases Sheba Medical Center, Tel-Hashomer, Israel; Rheumatology Unit, Department of Internal Medicine and Medical Specialities, Sapienza University of Rome, Rome, Italy.

Abstract
PROBLEM:
Post-vaccination autoimmune phenomena are a major facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and different vaccines, including HPV, have been identified as possible causes.
METHOD OF STUDY:
The medical history of three young women who presented with secondary amenorrhea following HPV vaccination was collected. Data regarding type of vaccine, number of vaccination, personal, clinical and serological features, as well as response to treatments were analyzed.
RESULTS:
All three patients developed secondary amenorrhea following HPV vaccinations, which did not resolve upon treatment with hormone replacement therapies. In all three cases sexual development was normal and genetic screen revealed no pertinent abnormalities (i.e., Turner’s syndrome, Fragile X test were all negative). Serological evaluations showed low levels of estradiol and increased FSH and LH and in two cases, specific auto-antibodies were detected (antiovarian and anti thyroid), suggesting that the HPV vaccine triggered an autoimmune response. Pelvic ultrasound did not reveal any abnormalities in any of the three cases. All three patients experienced a range of common non-specific post-vaccine symptoms including nausea, headache, sleep disturbances, arthralgia and a range of cognitive and psychiatric disturbances. According to these clinical features, a diagnosis of primary ovarian failure (POF) was determined which also fulfilled the required criteria for the ASIA syndrome.
CONCLUSION:
We documented here the evidence of the potential of the HPV vaccine to trigger a life-disabling autoimmune condition. The increasing number of similar reports of post HPV vaccine-linked autoimmunity and the uncertainty of long-term clinical benefits of HPV vaccination are a matter of public health that warrants further rigorous inquiry.

Study – Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12.

US National Library of Medicine
National Institutes of Health – Sep 2017

Donahue JG – 1, Kieke BA – 2, King JP – 3, DeStefano F – 4, Mascola MA – 5, Irving SA – 6, Cheetham TC – 7, Glanz JM – 8, Jackson LA – 9, Klein NP – 10, Naleway AL – 11, Weintraub E – 12, Belongia EA – 13.
Author information
1 Marshfield Clinic Research Institute, 1000 N. Oak Ave, Marshfield, WI 54449, United States. Electronic address: donahue.james@mcrf.mfldclin.edu.
2 Marshfield Clinic Research Institute, 1000 N. Oak Ave, Marshfield, WI 54449, United States. Electronic address: kieke.burney@mcrf.mfldclin.edu.
3 Marshfield Clinic Research Institute, 1000 N. Oak Ave, Marshfield, WI 54449, United States. Electronic address: king.jennifer@mcrf.mfldclin.edu.
4 Centers for Disease Control and Prevention, Immunization Safety Office, 1600 Clifton Road NE, MS-D26 Atlanta, GA 30333, United States. Electronic address: fxd1@cdc.gov.
5 Marshfield Clinic, Department of Obstetrics and Gynecology, 1000 N. Oak Ave, Marshfield, WI 54449, United States. Electronic address: mascola.maria@marshfieldclinic.org.
6 Kaiser Permanente Northwest, 3800 N. Interstate Ave, Portland, OR 97227, United States. Electronic address: stephanie.a.irving@kpchr.org.
7 Kaiser Permanente Southern California, 100 S. Los Robles Ave., 2nd Floor, Pasadena, CA 91101, United States. Electronic address: craig.t.cheetham@kp.org.
8 Kaiser Permanente Colorado, 10065 E. Harvard, Suite 300, Denver, CO 80231, United States. Electronic address: jason.m.glanz@kp.org.
9 Group Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA 98101, United States. Electronic address: jackson.l@ghc.org.
10 Kaiser Permanente Northern California, 1 Kaiser Plaza, 16th Floor, Oakland, CA 94612, United States. Electronic address: Nicola.Klein@kp.org.
11 Kaiser Permanente Northwest, 3800 N. Interstate Ave, Portland, OR 97227, United States. Electronic address: Allison.Naleway@kpchr.org.
12 Centers for Disease Control and Prevention, Immunization Safety Office, 1600 Clifton Road NE, MS-D26 Atlanta, GA 30333, United States. Electronic address: eiw8@cdc.gov.
13 Marshfield Clinic Research Institute, 1000 N. Oak Ave, Marshfield, WI 54449, United States. Electronic address: belongia.edward@marshfieldclinic.org.

Abstract

INTRODUCTION:
Inactivated influenza vaccine is recommended in any stage of pregnancy, but evidence of safety in early pregnancy is limited, including for vaccines containing A/H1N1pdm2009 (pH1N1) antigen. We sought to determine if receipt of vaccine containing pH1N1 was associated with spontaneous abortion (SAB).
METHODS:
We conducted a case-control study over two influenza seasons (2010-11, 2011-12) in the Vaccine Safety Datalink. Cases had SAB and controls had live births or stillbirths and were matched on site, date of last menstrual period, and age. Of 919 potential cases identified using diagnosis codes, 485 were eligible and confirmed by medical record review. Exposure was defined as vaccination with inactivated influenza vaccine before the SAB date; the primary exposure window was the 1-28days before the SAB.
RESULTS:
The overall adjusted odds ratio (aOR) was 2.0 (95% CI, 1.1-3.6) for vaccine receipt in the 28-day exposure window; there was no association in other exposure windows. In season-specific analyses, the aOR in the 1-28days was 3.7 (95% CI 1.4-9.4) in 2010-11 and 1.4 (95% CI 0.6-3.3) in 2011-12. The association was modified by influenza vaccination in the prior season (post hoc analysis). Among women who received pH1N1-containing vaccine in the previous influenza season, the aOR in the 1-28days was 7.7 (95% CI 2.2-27.3); the aOR was 1.3 (95% CI 0.7-2.7) among women not vaccinated in the previous season. This effect modification was observed in each season.
CONCLUSION:
SAB was associated with influenza vaccination in the preceding 28days. The association was significant only among women vaccinated in the previous influenza season with pH1N1-containing vaccine. This study does not and cannot establish a causal relationship between repeated influenza vaccination and SAB, but further research is warranted.

VAXXED TV – My son seized on the table after vaccines #vaxxed #DidYouKnow #Praybig

My 2 month old son died following vaccinations #vaxxed #DidYouKnow #Praybig

Mandates would have killed my son #vaxxed #DidYouKnow #Praybig

One of my children is vaccinated and one is not #vaxxed #DidYouKnow #Praybig

Vaccinated without my consent #vaxxed #DidYouKnow #Praybig

Vaccines injured my family #vaxxed #DidYouKnow #Praybig

Flu shot injured me #vaxxed #DidYouKnow #Praybig

My son has autism from vaccines #vaxxed #DidYouKnow #Praybig

Vaccines destroyed my family #vaxxed #DidYouKnow #praybig

The medical profession killed my son #vaxxed #DidYouKnow #Praybig

 

How to accept Jesus Christ as your personal Saviour

1 Corinthians 15 Authorized (King James) Version (AKJV)
1 Moreover, brethren, I declare unto you the gospel which I preached unto you, which also ye have received, and wherein ye stand;
2 by which also ye are saved, if ye keep in memory what I preached unto you, unless ye have believed in vain.
3 For I delivered unto you first of all that which I also received, how that Christ died for our sins according to the scriptures;
4 and that he was buried, and that he rose again the third day according to the scriptures:

Hebrews 6 Authorized (King James) Version (AKJV)
1 Therefore leaving the principles of the doctrine of Christ, let us go on unto perfection; not laying again the foundation of repentance from dead works, and of faith toward God,
2 of the doctrine of baptisms, and of laying on of hands, and of resurrection of the dead, and of eternal judgment.
3 And this will we do, if God permit.
4 For it is impossible for those who were once enlightened, and have tasted of the heavenly gift, and were made partakers of the Holy Ghost,
5 and have tasted the good word of God, and the powers of the world to come,
6 if they shall fall away, to renew them again unto repentance; seeing they crucify to themselves the Son of God afresh, and put him to an open shame.
7 For the earth which drinketh in the rain that cometh oft upon it, and bringeth forth herbs meet for them by whom it is dressed, receiveth blessing from God:
8 but that which beareth thorns and briers is rejected, and is nigh unto cursing; whose end is to be burned.

 

Advertisements

Flu Vaccine is the most Dangerous Vaccine in the U. S. based on Settled Cases for Injuries

Flu Vaccine is the most Dangerous Vaccine in the U. S. based on Settled Cases for Injuries
Attorney Howard Gold of Gold Law Firm, who settled a case for GBS due to a flu vaccine in 2011, remarked:
Petitioners have three (3) years from the onset of the injury (or two years from date of death) to file a claim. Gold states that the “Program is not used as much as it could be because the American public is just not aware of it. I receive at least 5 calls a month from individuals who cannot obtain compensation because the deadline has passed. They just found out about it too late. We all need to do a better job in getting the word out to the public that the Program exists.” (Source.)
In November 2013, a healthy 19-year old young man died from a routine exam that included the flu vaccine. Chandler Webb received the flu shot on October 15th, and then died on November 19th, 28 days later. Since the flu shot is considered safe in the medical field, doctors waited too long to suspect that the flu shot was causing Chandler’s rapidly deteriorating medical condition, according to his mother. She believes that if they had investigated the adverse reaction to the flu shot immediately, he might still be alive today.

Just a quick cursory view of cases that are being compensated by this vaccine court shows that the most cases, by far, are cases for GBS and the flu vaccine.
The U.S Court of Federal Claims provides a referral list of attorneys that specialize in representing clients wanting to file claims for vaccine damages. The list is here, and contains 123 attorneys.
One of the law firms representing clients in the Vaccine Court is Maglio, Christopher, & Toale. This law firm has actually listed cases they have settled in the past couple of years here.
From what appears to be some point in 2010 through 2013, they have settled 132 cases

Preliminary Results: Surveillance for Guillain-Barré Syndrome After Receipt of Influenza A (H1N1) 2009 Monovalent Vaccine — United States, 2009–2010
GBS incidence was calculated and compared for the vaccinated and unvaccinated populations, which were estimated by age group, using data from CDC’s Behavioral Risk Factor Surveillance System (BRFSS) and National 2009 H1N1 Flu Survey (NHFS) telephone survey data for the counties in the EIP catchment areas, using methods published previously (4). The total person-time of follow-up was calculated by multiplying the population under surveillance by the number of days since the start of surveillance, October 1, 2009. Person-time at risk for GBS in the vaccinated population was calculated by multiplying the number of vaccinees by 42 days (or the number of days from vaccination to the end of the surveillance period if <42 days) (1). Children aged 6 months–9 years who received a second dose of 2009 H1N1 vaccine were presumed to have received it 28 days after the first dose, as recommended by the Advisory Committee on Immunization Practices,¶ giving them an additional 28 days of person-time at risk. To calculate the corresponding person-time in the unvaccinated population, the person time at risk for GBS was summed among the vaccinated population and then subtracted from the total person-time of follow-up under surveillance.
Incidence among the vaccinated population was calculated by dividing the number of GBS cases vaccinated within the risk window by the total amount of person-time at risk following vaccination. Incidence among the unvaccinated population was calculated by dividing the number of GBS cases unexposed to vaccine or exposed to vaccine outside the risk window by the total amount of person-time unexposed to 2009 H1N1 vaccine. Bootstrapping methods were used to estimate 95% confidence intervals (CIs) for the rate ratios that incorporated the variance of vaccine coverage estimates (5). A Poisson distribution was assumed for the occurrence of cases and a normal distribution for the vaccine coverage estimates; the Mantel-Haenszel method was used for age-adjusted CIs. A temporal scan statistic was used to assess for any significant clustering in the interval between vaccination and illness onset in vaccinated cases (6).
During October 1, 2009–May 10, 2010, a total of 529 reports of potential GBS were identified by EIP, of which 326 met the GBS case criteria. Of the 326 persons with GBS, 27 had documentation of 2009 H1N1 vaccination in the 42 days preceding illness onset, 274 did not receive vaccine, and the vaccine status of 25 was either unknown (six) or pending ascertainment (19) (Table 1). Sixteen of the 27 (59%) with documentation of 2009 H1N1 vaccination also reported antecedent illness symptoms in the 42 days before GBS onset; 78% of unvaccinated persons with GBS (215 of 274) reported antecedent symptoms (p=0.04). No clustering among vaccinated persons was observed in the period between vaccination and illness onset (p=0.54). Among the 27 GBS patients with 2009 H1N1 vaccination, four required ventilator support, and one remained hospitalized 30 days after GBS onset; among the 274 GBS patients who did not receive 2009 H1N1 vaccination, 37 (14%) required ventilator support, and 34 (12%) remained hospitalized after 30 days. Eight (2%) of the 326 GBS patients died (from any cause); none of the eight had received the 2009 H1N1 vaccine within 42 days of illness onset.
Among patients hospitalized through March 31, 2010, comparison of the incidence of GBS among those who received 2009 H1N1 vaccine and those who did not receive the vaccine revealed an age-adjusted rate ratio of 1.77 (CI = 1.12–2.56) (Table 2). If this preliminary rate ratio is confirmed in end-of-surveillance analyses, the attributable rate of GBS would be 0.71 per 100,000 person-years, corresponding to an attributable risk of 0.8 excess cases of GBS per 1 million vaccinations.**

Risk of Guillain-Barré Syndrome Following H1N1 Influenza Vaccination in Quebec
RESULTS
During the active surveillance period, 61 possible GBS cases were reported to public health authorities. Seventy-seven possible GBS cases were retrospectively identified in the MEDECHO hospital admission database. Thirty-seven cases were found in both sources, for a total of 101 cases. For all 101, medical charts were retrieved and analyzed. Eighteen possible cases were excluded: 12 cases with a final diagnosis other than GBS, 2 recurrent GBS cases, 2 cases with disease onset before October 13, 2009, and 2 other cases with onset after March 31, 2010. Thus, 83 cases were included in the analysis. The overall GBS incidence rate in the study population, representing 3 623 046 person-years of observation, was 2.3 per 100 000.
Of the 83 confirmed GBS cases included in the analysis, 42 had been immunized before disease onset (1-121 days after immunization) and all had received the ASO3 adjuvant H1N1 vaccine. For 25 cases, disease onset was 8 or fewer weeks after the vaccine was administered and they were considered exposed, whereas the 17 other cases were immunized more than 8 weeks before disease onset and were considered unexposed. Thus, for the cohort analysis, 25 GBS cases were considered exposed and 58 cases were considered unexposed.
The characteristics of GBS cases according to exposure status are shown in Table 1. Forty-nine cases were classified in the Brighton level 1 category, 22 cases in level 2, and 12 cases in level 4. The distribution of cases according to diagnostic category was similar in exposed and unexposed cases. The percentage of male patients was 69%. The median age was 49 years (range, 1-89 years). The percentage of elderly patients was higher in the exposed group than the unexposed group. The majority of patients (96%) were hospitalized; 25% developed severe paralysis of the lower limbs and were unable to walk at some point; and 17% developed respiratory distress syndrome and required intubation and/or assisted ventilation. Four patients died, all of whom were older than 60 years. Conditions occurring within 1 month before GBS onset as reported in medical records included a respiratory tract infection or influenzalike illness in 36% of cases, gastroenteritis in 18%, and trauma in 4%. A history of infection during the month prior to hospitalization was less frequent in exposed than in unexposed patients. The median interval between disease onset and hospitalization was 5 days (range, 1-34 days).
Of the 83 confirmed GBS cases identified during the 6-month study period, 56 (67% of total) occurred during a 12-week period from October 18, 2009 (2009 Centers for Disease Control and Prevention [CDC] week 42) to January 9, 2010 (2010 CDC week 1). The cluster was mostly explained by cases occurring in persons who were recently (≤8 weeks) immunized (22/56). Details on the distribution of cases are provided in eFigure 1.

Study: Increased Risk of Noninfluenza Respiratory Virus Infections Associated With Receipt of Inactivated Influenza Vaccine

Increased Risk of Noninfluenza Respiratory Virus Infections Associated With Receipt of Inactivated Influenza Vaccine
We randomized 115 children to trivalent inactivated influenza vaccine (TIV) or placebo. Over the following 9 months, TIV recipients had an increased risk of virologically-confirmed non-influenza infections (relative risk: 4.40; 95% confidence interval: 1.31-14.8). Being protected against influenza, TIV recipients may lack temporary non-specific immunity that protected against other respiratory viruses.
Influenza vaccination is effective in preventing influenza virus infection and associated morbidity among school-aged children [1, 2]. The potential for temporary nonspecific immunity between respiratory viruses after an infection and consequent interference at the population level between epidemics of these viruses has been hypothesized, with limited empirical evidence to date, mainly from ecological studies [3–15]. We investigated the incidence of acute upper respiratory tract infections (URTIs) associated with virologically confirmed respiratory virus infections in a randomized controlled trial of influenza vaccination.